| 0 (0%) | 04-18 17:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3532 | 1-year : | 4125.38 |
| Resists | First : | 3023.97 | Second : | 3532 |
| Pivot price | 2920.34 |
|||
| Supports | First : | 2834.87  |
Second : | 2717.98 |
| MAs | MA(5) : | 2929.49 |
MA(20) : | 2918.72 |
| MA(100) : | 2534.93 |
MA(250) : | 2203.3 |
|
| MACD | MACD : | 49 |
Signal : | 61.7 |
| %K %D | K(14,3) : | 44.8 |
D(3) : | 53 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 3023.97 | Low : | 1768.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CMG ] has closed above bottom band by 40.9%. Bollinger Bands are 32.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2943.4 - 2964.14 | 2964.14 - 2980.25 |
| Low: | 2858.55 - 2880.74 | 2880.74 - 2897.96 |
| Close: | 2879.38 - 2913.27 | 2913.27 - 2939.58 |
Tue, 16 Apr 2024
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are ... - The Globe and Mail
Tue, 12 Dec 2023
AbelZeta Presents Data from Two Clinical Studies Relating to its Immuno-Oncology Drug Development at the 65th ASH ... - PR Newswire
Mon, 20 Nov 2023
CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc. - Yahoo Finance
Mon, 20 Nov 2023
Rockville's CBMG Holdings announces name change - Maryland Daily Record
Wed, 27 Sep 2023
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate ... - PR Newswire
Fri, 05 May 2023
Longevity investment bulletin: CBMG, NeuroSense, D&D Pharmatech and more - Longevity.Technology
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.72e+007 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 683 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.92e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.29 |
| Profit Margin | 2.4 % |
| Operating Margin | 12.4 % |
| Return on Assets (ttm) | 14.6 % |
| Return on Equity (ttm) | 13.3 % |
| Qtrly Rev. Growth | 9.87e+009 % |
| Gross Profit (p.s.) | 11.84 |
| Sales Per Share | 34.81 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 44.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 1,780 (M) |
| PE Ratio | 0 |
| PEG Ratio | 45.4 |
| Price to Book value | 106.51 |
| Price to Sales | 83.52 |
| Price to Cash Flow | 33.85 |
| Dividend | 0 |
| Forward Dividend | 756030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|